---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-015069"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:38:29.804579+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics shareholders approve reverse stock split authorization

## Summary
- Reverse split ratio range 1:10 to 1:80, exact ratio set by board; authorized until Nov 30, 2024.
- For: 6,198,812; Against: 5,364,151; Abstain: 23,186; no broker non-votes.
- Adjournment proposal also approved (6,308,531 for, 5,052,193 against) but not used.

## SEC filing metadata
- accession: 0001654954-23-015069
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/0001654954-23-015069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-015069
- JSON: https://secwatch.observer/filing/0001654954-23-015069.json
- Plain text: https://secwatch.observer/filing/0001654954-23-015069.txt

## Key facts
- Shareholder Votes
  TENAX THERAPEUTICS, INC. shareholders approved Approve amendment to certificate of incorporation to authorize a reverse stock split at the 2023-11-30 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-11-30
  source text: The vote for this proposal was 6,198,812 shares for, 5,364,151 shares against, 23,186 shares abstaining, and no broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/0001654954-23-015069-index.htm
- Shareholder Votes
  TENAX THERAPEUTICS, INC. shareholders approved Adjournment of Special Meeting to permit further solicitation and vote of proxies at the 2023-11-30 meeting.
  - Outcome: passed
  - Meeting: 2023-11-30
  source text: The Adjournment Proposal was approved at the Special Meeting, with a vote of 6,308,531 shares for, 5,052,193 shares against, 225,425 shares abstaining, and no broker non-votes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/0001654954-23-015069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.